Clinical Trial

Fetal Brain Care: Therapies for Brain Neurodevelopment in Fetal Growth Restriction

Recruiting
View on ClinicalTrials.gov →
Summary
Singleton pregnancies being diagnosed of fetal growth restriction from 24 to 32.6 weeks of gestation will be randomized to two equally sized groups: maternal oral supplementation with Lactoferrin and DHA (Docosahexaenoic acid) or placebo.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2021-09-03; most recent amendment 2024-03-15.
Status change: Not Yet Recruiting → Recruiting 2023-03-01
Trial Details
NCT Number NCT05038462
Lead Sponsor Institut d'Investigacions Biomèdiques August Pi i Sunyer
Collaborators: Fundacion Clinic per a la Recerca Biomédica, Fundació Sant Joan de Déu
Conditions Fetal Growth Retardation, Intrauterine Growth Restriction
Enrollment 304 participants
Start Date 2023-01-18
Primary Completion 2026-09 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2024-03-18